Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · July 10, 2024

Amivantamab Plus Lazertinib vs Osimertinib for First-Line EGFR-Mutant Advanced NSCLC With Biomarkers of High-Risk Disease

Annals of Oncology


Additional Info

Annals of Oncology
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA
Ann. Oncol 2024 Jun 26;[EPub Ahead of Print], E Felip, BC Cho, V Gutiérrez, A Alip, B Besse, S Lu, AI Spira, N Girard, R Califano, SM Gadgeel, JC Yang, S Yamamoto, K Azuma, YJ Kim, KH Lee, P Danchaivijitr, CG Ferreira, Y Cheng, MAN Sendur, GC Chang, CC Wang, K Prabhash, Y Shinno, D Stroyakovskiy, L Paz-Ares, JR Rodriguez-Cid, C Martin, MRG Campelo, H Hayashi, D Nguyen, P Tomasini, M Gottfried, C Dooms, A Passaro, M Schuler, ACZ Gelatti, S Owen, K Perdrizet, SI Ou, JC Curtin, J Zhang, M Gormley, T Sun, A Panchal, M Ennis, E Fennema, M Daksh, S Sethi, JM Bauml, SH Lee

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading